Also from this source

You just read:

BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting

News provided by

BioDelivery Sciences International, Inc.

Mar 02, 2011, 08:00 EST